The Translational Genomics Research Institute (TGen) along with other key research institutes, which includes the Johns Hopkins University School of Medicine, the Mayo Clinic, and Memorial Sloan Kettering Cancer Center, found a new set of genes that can demonstrate improved survival for patients affected by pancreatic cancer after surgery. In addition, the study revealed that detecting circulating tumor DNA in the blood could offer a preliminary indication of tumor recurrence.
Dr. Daniel D. von Hoff, a TGen Distinguished Professor, Physician-in-Chief, Co-Director of TGen’s SU2C Pancreatic Cancer Dream Team, and Chief Scientific Officer at the Virginia G. Piper Cancer Center Clinical Trials at HonorHealth, stated in TGen’s article: “These observations provide predictors of outcomes in patients with pancreatic cancer and have implications for detection of tumor recurrence, and perhaps someday for early detection of the cancer”.
The study, Clinical implications of genomic alterations in the tumor and circulation of pancreatic cancer patients, was published in the journal Nature Communications on July 7th.
Read more on TGen’s News section: https://www.tgen.org/home/news/2015-media-releases/tgen-finds-genes-linked-to-pancreatic-cancer-survival.aspx#.Vd8qarTfK-I
The TGen Institute is a non-profit organization dedicated to helping patients with cancer, neurological disorders and diabetes. Check them out at: https://www.tgen.org
Learn more about TGen’s pancreatic cancer research: https://www.tgenfoundation.org/netcommunity/page.aspx?pid=983